Microbix Biosystems (TSE:MBX) Stock Passes Above Fifty Day Moving Average – Time to Sell?

Posted by Jeff Wilder on Jun 13th, 2026

Microbix Biosystems Inc. (TSE:MBX – Get Free Report) shares passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$0.25 and traded as high as C$0.30. Microbix Biosystems shares last traded at C$0.30, with a volume of 44,974 shares traded.

Microbix Biosystems Trading Up 5.3%

The company has a fifty day moving average of C$0.25 and a two-hundred day moving average of C$0.24. The company has a current ratio of 5.35, a quick ratio of 5.57 and a debt-to-equity ratio of 27.03. The stock has a market capitalization of C$41.25 million, a price-to-earnings ratio of -7.32 and a beta of 0.70.

Microbix Biosystems (TSE:MBX – Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported C($0.01) earnings per share for the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%.The company had revenue of C$3.38 million during the quarter. On average, research analysts expect that Microbix Biosystems Inc. will post 0.02 EPS for the current year.

Insiders Place Their Bets

In related news, Director Martin Marino bought 115,000 shares of Microbix Biosystems stock in a transaction that occurred on Thursday, May 28th. The stock was purchased at an average cost of C$0.28 per share, for a total transaction of C$32,200.00. Following the acquisition, the director owned 2,000,167 shares in the company, valued at C$560,046.76. This trade represents a 6.10% increase in their ownership of the stock. In the last three months, insiders purchased 230,500 shares of company stock valued at $62,325. 14.00% of the stock is currently owned by insiders.

Microbix Biosystems Company Profile

(Get Free Report)

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.